Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies

Trial Profile

Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Rituximab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms BIORA
  • Sponsors Biocad
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Aug 2016 Status changed from active, no longer recruiting to completed according to results presented at the 17th Annual congress of the European League Against Rheumatism.
    • 12 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top